Phase 2 trial recruiting: revert hormone resistance with apalutamide and ENV105
In phase 1 it worked with 44% of patients it seems, it's multisite, it could be worth trying for our warrior with mCRPC (metastatic castrate resistant...
In phase 1 it worked with 44% of patients it seems, it's multisite, it could be ...